At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 56 enrolled
Drug / intervention
Panitumumab +2 moredrug
Likely dose
Panitumumab 6 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Multicenter Trial of Panitumumab, Nivolumab, and Ipilimumab for KRAS/NRAS/BRAF Wild-type MSS Refractory Metastatic Colorectal Adenocarcinoma
In Brief
A Phase 2 clinical trial evaluating Panitumumab, Nivolumab, and 1 other intervention for Colon Cancer. Completed, enrolled 56 participants across 5 sites.
Detailed Summary
To investigate the combination of nivolumab and ipilimumab with panitumumab in subjects with unresectable, refractory, KRAS/NRAS/BRAF wild-type, microsatellite stable (MSS) metastatic colorectal cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColon Cancer
CountriesUnited States
CollaboratorsAmgen, Bristol-Myers Squibb
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartMar 2018
Primary CompletionSep 2020
Study CompletionDec 2024
TodayJul 2026
First PostedFeb 22, 2018
Enrollment StartMar 9, 2018
Primary CompletionSep 21, 2020
Study CompletionDec 2, 2024
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 8.4 years ago
Interventions
Panitumumabdrug
6 mg/kg via IV every 2 weeks in combination with nivolumab and ipilimumab
Nivolumabdrug
240 mg via IV every 2 weeks in combination with panitumumab and ipilimumab
Ipilimumabdrug
1 mg/kg via IV every 6 weeks in combination with nivolumab and panitumumab